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Background: The Global Anticoagulant Registry in the FIELDeAtrial Fibrillation (GARFIELD-AF) is an
ongoing prospective noninterventional registry, which is providing important information on the base-
line characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-
valvular atrial ﬁbrillation (NVAF). This report describes data from Indian patients recruited in this registry.
Methods and results: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these,
1388patientswere recruited from26siteswithin India (2012e2016). In India, themeanagewas65.8yearsat
diagnosis of NVAF. Hypertensionwas themost prevalent risk factor for AF, present in 68.5% of patients from
Indiaand in76.3%ofpatients globally (P<0.001).Diabetesandcoronaryarterydisease (CAD)wereprevalent
in 36.2%and28.1%of patients as comparedwith global prevalence of 22.2%and21.6%, respectively (P<0.001
for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing
stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K
antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients
[median INR value 1.6 (interquartile range {IQR}: 1.3e2.3) versus 2.3 (IQR 1.8e2.8) (P < 0.001)]. Compared
with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100
person-years (95% conﬁdence interval 6.32e9.35) vs 4.34 (4.16e4.53), P < 0.0001], while rates of stroke/
systemic embolism and major bleeding were lower after 1 year of follow-up.
Conclusion: Compared to previously published registries from India, the GARFIELD-AF registry describes
clinical proﬁles and outcomes in Indian patients with AF of a different etiology. The registry data
show that compared to the rest of the world, Indian AF patients are younger in age and have more
diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy
with VKA but are underdosed compared with the global average in the GARFIELD-AF.
Clinical trial registrationdURL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT01090362.
© 2018 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Sir Ganga Ram Hospital, Sir Ganga Ram Hospital Marg, Rajinder Nagar, New Delhi, 110060, India.
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J.PS. Sawhney et al. / Indian Heart Journal 70 (2018) 828e835 8291. Introduction 2.2. Ethics statementAtrial ﬁbrillation (AF) is the most common arrhythmia
worldwide,1 with a prevalence of 1e2% in the general population.
AF is an important contributor to all-cause mortality, cognitive
decline, and stroke. The likelihood of nonvalvular AF (NVAF) in-
creases with advancing age and is often accompanied by the
presence of diabetes and cardiovascular comorbidities, such as
heart failure and coronary artery disease (CAD). In the recently
published Real-life global survey evaluating patients with atrial
ﬁbrillation (REALISE-AF) registry from India, the most common
underlying cardiovascular risk factors in patients with AF
were hypertension (50.8%) and diabetes (20.4%). In addition, a
high proportion of patients had a history of valvular heart disease
(40.7%).2,3
India has over 1.2 billion inhabitants4 and is undergoing
remarkable economic changes in the recent years and is making
important inroads into improving cardiovascular health care
despite ﬁnite resources. By the year 2050, however, the aging
population (60e80 years) is projected to increase by 326% and for
patients 80 years, by 700%.5 As aging is a risk factor for AF, this
change, along with other age-associated cardiovascular disease, is
likely to add to already high index levels of AF associated with
rheumatic heart disease.6,7
To date, most of our understanding of NVAF is based on obser-
vational studies fromNorth America andwestern Europe.8 Recently
published registry data from the Indian Heart Rhythm Society
(IHRS-AF) registry9; Randomised Evaluation of Long-Term Anti-
coagulation Therapy registry10; and REALISE-AF registry2,3 have
described patients with rheumatic valvular heart disease (RVHD) as
well as those with NVAF.
Global Anticoagulant Registry in the FIELDeAtrial Fibrillation
(GARFIELD-AF)11 is one of the ﬁrst studies to evaluate patients with
only NVAF in Indiadthereby allowing a comparison of similar pa-
tients from the rest of the world. Patients in the GARFIELD-AF were
enrolled from35 countries between 2010 and 2016 and are currently
being followed up until 2018 when all patients will have had a
minimumfollow-upof2years andupto8years. This articledescribes
the trends in stroke prevention treatment and records the burden of
disease and one-year outcomes associated with NVAF in India.
2. Methods
2.1. Study design
The GARFIELD-AF is an ongoing prospective noninterventional
disease registry of patients with newly diagnosed, predominantly
NVAF (ClinicalTrials.gov Identiﬁer: NCT01090362).11 Patients
were enrolled into the GARFIELD-AF registry from over 1000
centers in 35 countries worldwide, from America, Europe, Africa,
and Asia. Eligible patients included men and women aged 18
years with NVAF, diagnosed according to standard local proced-
ures within the previous 6 weeks and with at least one additional
risk factor for stroke. Risk factors were neither prespeciﬁed in the
protocol nor were they limited to the components of existing risk
stratiﬁcation schemes. The registry excluded patients with a
transient reversible cause of AF and those for whom follow-up
was not envisaged or possible. Investigator sites were selected
randomly and represented the different care settings in each
participating country (ofﬁce-based practice; hospital depart-
mentsdneurology, cardiology, geriatrics, internal medicine, and
emergencydanticoagulation clinics; and general or family
practice).All patients provided written informed consent to participate.
Independent ethics committee and hospital-based institutional
review board approvals were obtained, as necessary, for the reg-
istry protocol. The registry is being conducted in accordance with
the principles of the Declaration of Helsinki, local regulatory re-
quirements, and the International Conference on Harmonisation-
Good Pharmacoepidemiological and Clinical Practice Guidelines.
2.3. Procedures and outcomes measures
Baseline data collected at screening included patients charac-
teristics,medical history, care setting, type of AF, date andmethod of
diagnosis, symptoms, and anticoagulant (AC) treatment [vitamin K
antagonists (VKAs), factor Xa inhibitors (FXas), and direct thrombin
inhibitors (DTIs), as well as antiplatelet (AP) treatment]. Ethnicity
was classiﬁed by the investigator in agreement with the patient.11
Data on all components of the CHA2DS2-VASc [congestive heart
failure (CHF), hypertension, diabetes, vascular disease, age 65e74
years, and female gender, age 75 years and previous systemic
embolism]12 and the HAS-BLED13 risk stratiﬁcation schemes were
collected to assess the risks of stroke and bleeding retrospectively.
Vascular disease was deﬁned as peripheral artery disease and/or
CAD with a history of acute coronary syndrome. Hypertension was
deﬁned as a documented history of hypertension or blood pressure
>140/90 mmHg at rest.
2.4. Data collection
GARFIELD-AF data were collected using an electronic case report
form(eCRF)andcapturedbytrainedpersonnel.TheeCRFwasdesigned
by Dendrite Clinical Systems Ltd, Henley-on-Thames, UK, the group
which is also responsible for the ongoing database programmanage-
ment. Oversight of operations and data management are managed by
the sponsor and coordinating center Thrombosis Research Institute
(TRI),with support fromQuintiles (Durham,NC,USA), theUniversityof
Birmingham Department of Primary Care Clinical Sciences (Birming-
ham, UK), Thrombosis Research Group-Brigham and Women's Hos-
pital (Boston, MA, USA), and AIXIAL (Paris, France).
The GARFIELD-AF protocol requires that 20% of all eCRFs are
monitored against source documentation, that there is an elec-
tronic audit trail for all data modiﬁcations, and that critical vari-
ables are subjected to additional audit.14
2.5. Statistical analysis
This article describes the baseline characteristics, treatment
patterns, and 1-year outcomes based on global data and for patients
recruited in India; data for these analyses were extracted from the
registry database on 18th October 2017. Continuous variables are
expressed as mean ± standard deviation (SD) and categorical var-
iables as frequency and percentage. Use of antithrombotic therapy
at baseline was analyzed by CHA2DS2-VASc and “modiﬁed” HAS-
BLED (excluding ﬂuctuations in the international normalized ra-
tio) scores, calculated retrospectively from the data collected. Pa-
tients with missing values were not removed from the study.
Prothrombin time and international normalized ratio (INR)
readings during the ﬁrst year of follow-up were included in the
analysis. Implausible INR values of less than 0.8 or greater than 20
were excluded. Patients on VKA treatment at enrollment, but with
fewer than three readings during the follow-up, were excluded
from the analysis. The distribution of INR values are described by
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range, and by the mean, SD, median, and interquartile range (IQR).
Occurrence of major clinical events (primarily, stroke/systemic
embolism (SE), major bleeding, and all-cause mortality) is
described using the number of events, the proportion of patients
with the event divided by the population at risk at the beginning of
the follow-up period, person-time event rate (per 100 person-
years), and 95% conﬁdence interval (CI). We estimated person-
year rates using a Poisson model, with the number of events.
Only the ﬁrst occurrences of each event were taken into account.
Data analysis was performed at the TRI with SAS, version 9.4 (SAS
Institute Inc., Cary, NC, USA).
3. Results
3.1. Baseline patient characteristics
In total, 52,014 patients with a new diagnosis of AF were
enrolled in the GARFIELD-AF between March 2010 and August
2016. Of these, 1388 of patients were from India recruited between
August 2012 and August 2016 from 26 centers Fig. 1. The mean
(SD) time between enrollment and recruitment was 1.4 (1.5)
weeks. The proportion of patients recruited by cohort is reportedFig. 1. GARFIELD-AF sites in India. GARFIELD-AF, Global Ain Supplementary Figure S1. Indian patients with NVAF in this
registry were almost entirely diagnosed and managed by cardi-
ologists (81.7%), with a small number of patients diagnosed by
internal medicine (15.0%), neurology (1.2%), and primary care
physicians (1.9%). Approximately nine of 10 patients were
managed in the hospital setting (90.1%); a small number of pa-
tients were ﬁrst attended to by emergency services (2.7%).
Approximately 8% of the patients made use of private medical
insurance for their care.
The baseline clinical characteristics of patients recruited in India
and all countries are summarized in Table 1. In India, majority
(59.9%) of the patients were men; mean age at diagnosis of NVAF
was 65.8 years, and 26.3% of the patients were 75 years. Hyper-
tension was the most prevalent risk factor for AF, seen in 68.5% of
patients from India and in 76.3% of patients globally. A lower body
mass index (BMI) (average of 24.3 kg/m2) was observed in patients
from India compared with a global BMI average of 27.8 kg/m2
(P < 0.001). Despite this, diabetes was prevalant in over a third of
Indian patients (36.2%), a signiﬁcantly higher proportion than pa-
tients globally (22.2%, P < 0.001).
Cardiovascular comorbidities, such as CAD, were higher for pa-
tients from India than globally (28.1% vs 21.6%, P < 0.001) at the
time of diagnosis of AF. Congestive heart failure (CHF) wasnticoagulant Registry in the FIELDeAtrial Fibrillation.
Table 1
Baseline characteristics of patients recruited from India and all countries in the GARFIELD-AF registry.
Variable India (N ¼ 1388) All countries (N ¼ 52,014) P-Valueb
Mean age (SD), years 65.8 (12.2) 69.7 (11.5) <0.001
Age 75 years, % 26.3 37.2 <0.001
Women, % 40.1 44.2 0.002
Mean BMI (SD), kg/m2 24.3 (4.3) 27.8 (5.7) <0.001
Smoking, current/Ex, % 16.0 34.6 <0.001
Alcohol consumption, % 16.4 44.5 <0.001
Diabetes mellitus, % 36.2 22.2 <0.001
History of hypertension, % 68.5 76.3 <0.001
Hypercholesterolaemia, % 13.6 41.6 <0.001
Coronary artery disease, % 28.1 21.6 <0.001
Congestive heart failure % 15.5 20.0 <0.001
Prior stroke/transient ischemic attack, % 9.1 11.4 0.005
Vascular diseasea,% 14.1 14.8 0.452
Chronic kidney diseasey (grade 3), % 5.2 10.3 <0.001
Type of AF, %
Paroxysmal 16.4 27.5 <0.001
Permanent 8.5 12.8 <0.001
Persistent 10.4 14.9 <0.001
New/unclassiﬁed 64.6 44.8 <0.001
Care setting at diagnosis, %
Cardiology 81.7 65.7 <0.001
Geriatrics 0.3 0.4 <0.001
Internal medicine 15.0 18.0 <0.001
Neurology 1.2 1.7 <0.001
Primary care/general practice 1.9 14.2 <0.001
Median time since diagnosis (IQR), weeks 0.70 (0.20e2.00) 1.40 (0.50e3.20) <0.001
CHA2DS2-VASc scores, mean (SD) 2.9 (1.5) 3.2 (1.6) <0.001
HAS-BLED, mean (SD) 1.5 (0.9) 1.4 (0.9) 0.002
AF, atrial ﬁbrillation; BMI, body mass index; IQR, interquartile range; SD, standard deviation.
y Renal function was assessed according to the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative classiﬁcation by investigators at baseline.
a Peripheral artery disease or coronary artery disease.
b P-values were calculated for India vs all other countries.
Fig. 2. Antithrombotic treatment in patients enrolled in ﬁve sequential cohorts: C1 (2010e2011), C2 (2011e2012), C3 (2013e2014), C4 (2014e2015), and C5 (2015e2016), com-
parison of India versus world data from the GARFIELD-AF registry. GARFIELD-AF, Global Anticoagulant Registry in the FIELDeAtrial Fibrillation.
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(P < 0.001). Nearly one-tenth of the patients had a history of
transient ischaemic attack or prior stroke in India and all countries.
In this registry of NVAF, a very low percentage of patients had RVHD
globally (0.1%) and none from India. Prevalence of chronic kidney
disease was 5.2% in India and 10.3% globally (P < 0.001).The mean (±SD) CHA2DS2-VASc scores in India and all countries
were 2.9 (1.5) and 3.2 (1.6), respectively (P < 0.001). Figure S2 in the
Supplementary Material shows the distribution of patients across
the range of CHA2DS2-VASc scores in India and all countries. Pro-
portionately, there were more Indian patients with low stroke risk
(CHAD2DS2-VASc 3).
Fig. 3. Treatment of newly diagnosed AF by CHA2DS2-VASc score in (A) India and (B) all countries included in the GARFIELD-AF registry. AF, atrial ﬁbrillation; GARFIELD-AF, Global
Anticoagulant Registry in the FIELDeAtrial Fibrillation.
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unclassiﬁed type of AF diagnosed. The most prevalent form of AF
was paroxysmal AF (16.4%) in patients; followed by persistent
(10.4%) and permanent AF (8.5%).
3.2. Antithrombotic treatment
Fig. 2 shows the patterns of antithrombotic treatment in each
cohort for India and all countries. Overall, patients were enrolled
in four sequential cohorts (C): 317 in C2 (2011e2012), 334 in C3
(2013e2014), 242 in C4 (2014e2015), and 495 in C5 (2015e2016).
In India and globally, antithrombotic therapy was prescribed to
approximately 80% of the patients, whereas approximately 20% of
the patients were not prescribed antithrombotic treatment. The
most common antithrombotic treatment in India was AP therapy
alone, in around 40% of the patients within each cohort. The mostcommonly prescribed oral AC for stroke prevention at diagnosis
of AF was VKA ± AP therapy (in approximately 40% overall), and
only few patients received Novel Oral Anticoagulant (NOAC) ± AP
therapy (approximately 6%); this trend did not change appre-
ciably over time in India.3.3. Risk proﬁles and treatment patterns
Fig. 3 shows the distribution of antithrombotic therapies ac-
cording to the CHA2DS2-VASc scores. In Indiawith increasing stroke
risk, there was a marked increase in the proportions (from 20% to
50%) of patients receiving oral AC ± AP therapy and fewer patients
receiving no therapy (from 31.6% to 6.8%). The proportions of pa-
tients receiving AP therapy alone remained consistent despite the
increasing risk of stroke.
Fig. 4. HAS-BLED scores at baseline in patients with newly diagnosed AF: India versus
all countries included in the GARFIELD-AF registry. AF, atrial ﬁbrillation; GARFIELD-AF,
Global Anticoagulant Registry in the FIELDeAtrial Fibrillation.
Fig. 5. Treatment of newly diagnosed AF by HAS-BLED score in (A) India and (B) all count
Anticoagulant Registry in the FIELDeAtrial Fibrillation.
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Fig. 4 shows the HAS-BLED risk proﬁle of patients in India and all
countries. As reﬂected in the mean HAS-BLED scores, patients in
India have a slightly higher risk of bleeding compared with the
global average (SD): 1.5 (0.9) vs 1.4 (0.9) (P ¼ 0.002).
Fig. 5a shows that Indian patients with highest risk of bleeding
are more likely to receive AC ± AP than patients with no risk or low
risk of bleeding. An increase in patients receiving NOAC therapy is
shown for the highest risk patients (particularly HAS-BLED score of
4e9).
3.5. INR readings and time in therapeutic range
A total of 368 INR readings were analyzed from 407 Indian pa-
tients receiving VKA; excluding those who had <3 INR readings.
Globally, 158,121 INR readings were analyzed from a total of 20,182ries included in the GARFIELD-AF registry. AF, atrial ﬁbrillation; GARFIELD-AF, Global
Table 2
Event rates per 100 person-years for stroke, major bleeding, and all-cause mortality.
India (N ¼ 1388) All countries (N ¼ 52,014) P-valuea
Events Rate (95% CI) Events Rate (95% CI)
All-cause mortality 100 7.68 (6.32e9.35) 2140 4.34 (4.16e4.53) <0.0001
Cardiovascular death 44 3.38 (2.52e4.54) 799 1.62 (1.51e1.74) <0.0001
Noncardiovascular death 19 1.46 (0.93e2.29) 793 1.61 (1.50e1.72) 0.6621
Undetermined cause 37 2.84 (2.06e3.92) 548 1.11 (1.02e1.21) <0.0001
Stroke/systemic embolism 11 0.85 (0.47e1.53) 657 1.34 (1.24e1.45) 0.1230
Major bleeding 4 0.31 (0.12e0.82) 411 0.84 (0.76e0.92) 0.0364
Acute coronary syndrome 5 0.38 (0.16e0.92) 377 0.77 (0.69e0.85) 0.1072
CI, conﬁdence interval.
a P-values were calculated for India vs all other countries using KaplaneMeier analysis with the generalized Wilcoxon test producing the P-value.
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the median INR value was 1.6 (IQR: 1.3e2.3) in India and 2.3 (IQR
1.8e2.8), globally (P < 0.001). Approximately two-thirds of INR
readings (64.1%) in India were <2.0 and 25.2% between 2.0 and 3.0
(Supplementary Table S1).3.6. Events rates at 1-year follow-up and clinical outcomes
Event rates per 100 person-years during the ﬁrst year after
diagnosis of AF in GARFIELD-AF are presented in Table 2. Patients
from India had markedly higher rates of all-cause mortality
compared with all countries [7.68 per 100 person-years (95% CI
6.32e9.35) vs 4.34 (4.16e4.53), P < 0.0001]. Rates per 100 person-
years of stroke/systemic embolism and major bleeding were lower
in India compared with global average in the GARFIELD-AF [0.85
(0.47e1.53) vs. 1.34 (1.24e1.45), P ¼ 0.1230 and 0.31 (0.12e0.82) vs
0.84 (0.76e0.92), P ¼ 0.0364]. Overall, the incidence of cardiovas-
cular events was higher in Indian patients. The causes of death
during the ﬁrst year of follow-up are presented in Supplementary
Table S2. Of all the cardiovascular causes of death, the most com-
mon were sudden or unwitnessed death (27.3%) and congestive
heart failure (25%). Among the noncardiovascular causes of death,
respiratory failure was the most frequent (26.3%). All stroke events
of a known type were primary ischemic (0.79%)What is already known?
 The combined prevalence of valvular and NVAF treated
with vitamin K antagonists only in tertiary care centers of
India.
What this study adds?
 The prevalence of NVAF in the community and treatment
with both vitamin K antagonists and NOACs.
 Treatment with NOACs in nonvalvular AF was missing in
the past.4. Discussion
This is the ﬁrst report of the GARFIELD-AF data of patients from
India. The GARFIELD-AF describes an Indian population which is
older than those described in previous registries from
India.2,9,10,15e18 None of the patients in the GARFIELD-AF registry
had RVHD compared with 40%e60% of patients from other regis-
tries from India,9,10,19,20 thus representing an etiologically different
form of AF than has been previously published.
The use of antithrombotic therapy and its monitoring are major
challenges for the health-care system in India because of poor INR
monitoring and lack of compliance by patients.9 In India, the most
commonly prescribed antithrombotic for stroke prevention
(regardless of stroke risk) was AP therapy alone, although AP is no
longer recommended by Asian guidelines.21 The European Society
of Cardiology and National Institute for Health and Clinical
Excellence guidelines also restrict the use of aspirin and other AP
therapies for patients who refuse anticoagulation.22
There was, however, a notable increase in VKA prescribing (and
marked reduction in patients receiving no antithrombotic therapy)
with increasing stroke risk. By contrast, NOACs were seldom pre-
scribed, except for a slight increase in NOAC prescribing in patients
with thehighest risk of stroke. This couldbedue to the laterapprovals
of NOACs in India. Possible economic limitations and other factors in
India could also be affecting prescribing practices. NOACs are moreexpensive incomparisonwithVKA;however, in the long term,NOACs
mightprove to be themore cost-effective treatment choice compared
with VKA treatment,23 primarily because of lower monitoring costs
and reduced numbers of patients with stroke and SE.22 Practical
guidelines on themanagementof strokeprevention inAF (SPAF)with
NOACs in Asians, including Indians, have been published recently by
Dalal et al24 for the SPAF Academy India experts. Unlike many coun-
tries, the GARFIELD-AF registry has not observed any deﬁnitive in-
crease inNOACs prescribing in India over time (as shown in Fig. 2). Of
note, there are only 4000 cardiologists in India, and the ratio of
physicians to cardiac patients is disproportionately low25 compared
with other countries. This could also be a factor inﬂuencing antith-
rombotic therapy prescription patterns in India.
In India, the rate of all-cause mortality was higher than the
global rate. This is due to the higher rate of cardiovascular deaths.
The higher mortality was predominantly due to sudden death, CHF,
myocardial infraction, and stroke. Comorbidities such as hyper-
tension, CAD, and diabetes possibly resulted in higher mortality in
AF, and these outcome results were comparable to the published
results from the IHRS-AF registry.95. Conclusions
In conclusion, the global GARFIELD-AF registry continues to
provide important information on the homogeneity and hetero-
geneity of baseline characteristics and treatment patterns in pa-
tients with newly diagnosed AF. Compared to the rest of the world,
Indian patients are younger but associated with more diabetes and
CAD. Patients with a higher stroke risk are likely to receive AC
therapy with warfarin (compared with global average in the
GARFIELD-AF registry), but tend to be underdosed as suggested by
the INR. The registry provides evidence of highermortality in newly
diagnosed AF in India as compared with the global average in
GARFIELD-AF.
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